Animal experiment:

Mice[2]Meticrane is dissolved in DMSO to a concentration of 160 mg/mL. BALB/c (H-2d) mice receive daily i.p. injections at a dose of 400 mg/kg bodyweight for 10 days post anti-CTLA4 treatment. The thiazide diuretic Meticrane is used at doses of 150-300 mg once daily; the reported LD50 for mice is 10 g/kg after i.p. administration. 3 groups of standard BALB/c mice are treated consecutively (n=3/group) with increasing doses of Meticrane i.p. (100 mg/kg; 200 mg/kg and 400 mg/kg) for 10 days and monitored weight and general wellbeing.

Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

Meticrane, a thiazide diuretic is highly ranked in the connectivity map (cMap) analysis, and it does not have any known anti-cancer or immune-stimulating effect. Co-treatment with Meticrane significantly enhances treatment efficacy of CTLA-4 blockade[2].

References:
[1]. Rumiko TANAKA, et al. Crystal Structure of Meticrane. ANALYTICAL SCIENCES 2007, VOL. 23.
[2]. Lesterhuis WJ, et al. Network analysis of immunotherapy-induced regressing tumours identifies novel synergisticdrug combinations. Sci Rep. 2015 Jul 21;5:12298.